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therapy increased significantly for physicians in the inter-
vention group compared to physicians in the control
group during the post-intervention period (P  0.02).
This increase in eradication utilization was not accompa-
nied by a significant increase in the total cost of drug
therapy per patient for the intervention group compared
to the control group (P  0.82). The results from a 9-month
follow-up period will be presented. CONCLUSIONS:
The main goal of the study, to increase the utilization of
eradication therapy, was achieved in the 3-month follow-
up period. Observable modification of physician behav-
ior in only a three-month period is a positive finding, and
may indicate an even greater impact when the program is
evaluated over a longer period of time.
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OBJECTIVES: The optimal management strategy for pa-
tients with symptoms of GERD remains undefined. Our
objective was to examine the clinical and economic im-
pact of competing management strategies. METHODS:
Decision analysis was used to compare a traditional
“step-up” strategy with sequential invasive diagnostic
testing as needed to a strategy utilizing the initial “PPI
test” followed by a “step-down” approach with sequen-
tial diagnostic testing as needed. The cost per symptom-
free patient was assessed at 1-year. Systematic literature
review, Medicare payments and drug AWPs were used to
derive probability and cost estimates for the model.
Where there was uncertainty in the literature, estimates
were chosen to bias the model in favor of the traditional
management strategy. RESULTS: The average cost per
patient was $1045 and $1172 for the traditional “step-
up” and PPI test strategies, respectively. The percentage
of patients symptom-free at 1 year was 50% and 75%
for the traditional and PPI test strategies, respectively.
The incremental cost-effectiveness ratio for the PPI test
strategy was $510 per additional symptomatic cure. The
traditional strategy resulted in a greater than 5-fold in-
crease in endoscopy utilization but a 47% reduction in
ambulatory pH monitoring use. The reduced effective-
ness of the traditional strategy may be attributed to a
118% increase in the use of high-dose H2RAs while re-
ducing the use of PPIs by 42%–57%. The PPI test strat-
egy remained most cost-effective as long as the sensitivity
of the PPI test was greater than 23% and more than 47%
of patients with a positive PPI test received a “step-
down” trial. CONCLUSIONS: Strategies utilizing the
initial PPI test followed by a “step-down” approach may
result in improved symptom relief over 1 year, and more
appropriate utilization of invasive diagnostic testing at a
small marginal cost increase. These findings warrant a
prospective trial comparing these strategies.
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Recent work has shown that screening for Hepatitis C is
cost-effective from a societal perspective. Safety-net hos-
pitals are committed to providing care for their many un-
insured and underinsured patients who are unable to
pay. Adopting a screening policy would commit the insti-
tution to pay for expensive treatment for many of the
screened positives. OBJECTIVE: Examine the economic
implications for a safety-net hospital that adopts a Hepa-
titis C screening policy. METHODS: A Markov decision
analytic model was constructed, using a reference case of
a 35 year-old male without symptoms of Hepatitis C. The
perspective adopted was a safety-net hospital. Two popu-
lations were examined: uninsured, and insured, but with-
out coverage for combination interferonribavirin. Screen-
ing consisted of ELISA followed by a confirmatory PCR.
It was assumed that PCR and virus genotyping were sent
to an outside laboratory. Data came from prior publica-
tions. Patients were considered to be patients of this facility
for 5 years. RESULTS: In the uninsured group, screening
costs an additional $245 per patient, with an incremental
cost-effectiveness ratio (ICER) of $12,300/QALY. As
prevalence of infection ranged from 0.8%–9%, the addi-
tional cost of screening ranged from $77–$587, and the
ICER from $11,500/QALY–$16,800/QALY. In the under-
insured group, screening was associated with an addi-
tional cost of $166 per patient, with an ICER of $8300/
QALY. Varying the prevalence produced additional costs
of $38–$427. CONCLUSIONS: Although ICERs would
appear to be cost-effective from a societal perspective,
this is less clear for hospitals that deal with hard budgets,
not the soft budget, cost-conscious environment assumed
by incremental cost-effectiveness analysis. Screening for
Hepatitis C may be an expensive policy to implement for
safety-net hospitals. Public funding to support a screen-
ing and treatment program may be well justified.
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